<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gomes AP</submitter><funding>European Research Council</funding><funding>NIA NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>435-443</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9050834</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(4)</volume><pubmed_abstract>The alteration of metabolic pathways is a critical strategy for cancer cells to attain the traits necessary for metastasis in disease progression. Here, we find that dysregulation of propionate metabolism produces a pro-aggressive signature in breast and lung cancer cells, increasing their metastatic potential. This occurs through the downregulation of methylmalonyl coenzyme A epimerase (MCEE), mediated by an extracellular signal-regulated kinase 2-driven transcription factor Sp1/early growth response protein 1 transcriptional switch driven by metastatic signalling at its promoter level. The loss of MCEE results in reduced propionate-driven anaplerotic flux and intracellular and intratumoral accumulation of methylmalonic acid, a by-product of propionate metabolism that promotes cancer cell</pubmed_abstract><journal>Nature metabolism</journal><pubmed_title>Altered propionate metabolism contributes to tumour progression and aggressiveness.</pubmed_title><pmcid>PMC9050834</pmcid><funding_grant_id>F31 CA220750</funding_grant_id><funding_grant_id>R35 CA197588</funding_grant_id><funding_grant_id>R00 CA218686</funding_grant_id><funding_grant_id>DP2 AG077698</funding_grant_id><funding_grant_id>R01 CA046595</funding_grant_id><funding_grant_id>711486</funding_grant_id><funding_grant_id>P01 CA120964</funding_grant_id><pubmed_authors>Drapela S</pubmed_authors><pubmed_authors>Blenis J</pubmed_authors><pubmed_authors>Schild T</pubmed_authors><pubmed_authors>Ilter D</pubmed_authors><pubmed_authors>Fendt SM</pubmed_authors><pubmed_authors>Low V</pubmed_authors><pubmed_authors>Elia I</pubmed_authors><pubmed_authors>Mutvei AP</pubmed_authors><pubmed_authors>Nunes JB</pubmed_authors><pubmed_authors>Mullarky E</pubmed_authors><pubmed_authors>Rosenzweig A</pubmed_authors><pubmed_authors>Nagiec M</pubmed_authors><pubmed_authors>Schaffer BE</pubmed_authors><pubmed_authors>Gomes AP</pubmed_authors><pubmed_authors>Asara JM</pubmed_authors><pubmed_authors>Cantley LC</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>Broekaert D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Altered propionate metabolism contributes to tumour progression and aggressiveness.</name><description>The alteration of metabolic pathways is a critical strategy for cancer cells to attain the traits necessary for metastasis in disease progression. Here, we find that dysregulation of propionate metabolism produces a pro-aggressive signature in breast and lung cancer cells, increasing their metastatic potential. This occurs through the downregulation of methylmalonyl coenzyme A epimerase (MCEE), mediated by an extracellular signal-regulated kinase 2-driven transcription factor Sp1/early growth response protein 1 transcriptional switch driven by metastatic signalling at its promoter level. The loss of MCEE results in reduced propionate-driven anaplerotic flux and intracellular and intratumoral accumulation of methylmalonic acid, a by-product of propionate metabolism that promotes cancer cell</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-05-18T12:50:04.805Z</modification><creation>2025-02-19T03:24:14.321Z</creation></dates><accession>S-EPMC9050834</accession><cross_references><pubmed>35361954</pubmed><doi>10.1038/s42255-022-00553-5</doi></cross_references></HashMap>